- Home
- TOVX vs NCLH Comparison
TOVX vs NCLH Comparison
Compare TOVX & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- NCLH
- Stock Information
- Founded
- TOVX 2001
- NCLH 1966
- Country
- TOVX United States
- NCLH United States
- Employees
- TOVX N/A
- NCLH N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- NCLH Marine Transportation
- Sector
- TOVX Health Care
- NCLH Consumer Discretionary
- Exchange
- TOVX Nasdaq
- NCLH Nasdaq
- Market Cap
- TOVX 4.5M
- NCLH 11.5B
- IPO Year
- TOVX 2006
- NCLH 2013
- Fundamental
- Price
- TOVX $0.41
- NCLH $25.40
- Analyst Decision
- TOVX Hold
- NCLH Buy
- Analyst Count
- TOVX 1
- NCLH 19
- Target Price
- TOVX N/A
- NCLH $28.33
- AVG Volume (30 Days)
- TOVX 359.6K
- NCLH 16.7M
- Earning Date
- TOVX 11-11-2025
- NCLH 10-30-2025
- Dividend Yield
- TOVX N/A
- NCLH N/A
- EPS Growth
- TOVX N/A
- NCLH 61.59
- EPS
- TOVX N/A
- NCLH 1.54
- Revenue
- TOVX N/A
- NCLH $9,560,994,000.00
- Revenue This Year
- TOVX N/A
- NCLH $8.19
- Revenue Next Year
- TOVX N/A
- NCLH $10.51
- P/E Ratio
- TOVX N/A
- NCLH $16.55
- Revenue Growth
- TOVX N/A
- NCLH 5.22
- 52 Week Low
- TOVX $0.37
- NCLH $14.21
- 52 Week High
- TOVX $4.20
- NCLH $29.29
- Technical
- Relative Strength Index (RSI)
- TOVX 47.72
- NCLH 52.73
- Support Level
- TOVX $0.38
- NCLH $25.06
- Resistance Level
- TOVX $0.45
- NCLH $27.18
- Average True Range (ATR)
- TOVX 0.02
- NCLH 0.91
- MACD
- TOVX 0.00
- NCLH -0.03
- Stochastic Oscillator
- TOVX 49.14
- NCLH 44.89
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.